London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other stocks that drop the most amid investor caution. Wall Street kicked off the first ...

HONG KONG, Feb. 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a ...

Tuesday, Summit Therapeutics plc (NASDAQ:SMMT), currently trading at $18.84, maintained a Buy rating from H.C. Wainwright, with analysts keeping a steadfast $44.00 price target on the stock.

Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Officer, Director; Summit Therapeutics Inc ...

Summit Therapeutics Inc (NASDAQ:SMMT) announced a clinical trial collaboration with Pfizer to evaluate Ivonescimab in combination with multiple Pfizer antibody drug conjugates in unique solid ...

Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Officer, Director; Summit Therapeutics Inc Manmeet ...

The Advancing Black Professionals Summit returns to Nashville for the third year in a row on Feb. 28. Black leaders from corporate America, entrepreneurship, and other industries will gather in ...

Summit Therapeutics emphasized its strategic progress with the Pfizer collaboration and expanded ivonescimab trials, including HARMONi-3 and HARMONi-7. The strong cash position supports its ...

Ivonescimab and the PD-1/VEGF bispecific antibodies have been a hot topic ever since Summit's partner Akesobio generated impressive phase 3 results in a head-to-head trial against Merck’s (MRK ...

Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $ ...